A Multiple Dose, Randomized, Placebo-controlled, Dose-escalating Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered MD-18 for Healthy Subjects with Overweight or Obesity
Latest Information Update: 25 Dec 2024
Price :
$35 *
At a glance
- Drugs MD 18 (Primary)
- Indications Obesity
- Focus Adverse reactions
- Sponsors Cohen Global
- 25 Dec 2024 New trial record